crossover randomized trial
NCT02049034
The Effect of Lixisenatide on Postprandial Lipid and Glucose Metabolism in Patients with Type 2 Diabetes
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Lixisenatide 20 ug subcutaneous once daily Lixisenatide | metformin; lifestyle: not reported | 8 | ||
| A2 | Placebo Placebo | metformin; lifestyle: not reported | 8 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Lixisenatide 20 ug subcutaneous once daily A1 | Placebo A2 | Whole trial ALL |
|---|---|---|---|---|
| age | mean (years) | 57.3 | ||
| age | se (years) | 1.9 | ||
| bmi | mean (kg/m2) | 30.3 | ||
| bmi | se (kg/m2) | 1.0 | ||
| hba1c | mean (percent) | 8.2 | ||
| hba1c | se (percent) | 0.3 | ||
| other male | n | 8 | ||
| weight | mean (kg) | 91.8 | 92.2 | |
| weight | se (kg) | 3.4 | 2.9 |
Results
12 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (2 lines; O01)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 4 | A1 | final | 7.2 percent | 0.3 | not stated; other; R0018624:Table 1 | ||
| 4 | A2 | final | 7.9 percent | 0.3 | not stated; other; R0018624:Table 1 |
Body weight change in kilograms (diabetes) (2 lines; O02)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 4 | A1 | final | 89.4 kg | 3.3 | not stated; other; R0018624:Table 1 | ||
| 4 | A2 | final | 90.7 kg | 3.1 | not stated; other; R0018624:Table 1 |
All cause mortality (2 lines; O20)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 8 | not stated; other; R0018624:Results | ||||
| A2 | events | 0 / 8 | not stated; other; R0018624:Results |
Hospitalization for heart failure (2 lines; O23)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 8 | not stated; other; R0018624:Results | ||||
| A2 | events | 0 / 8 | not stated; other; R0018624:Results |
Serious adverse events (2 lines; O25)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 8 | not stated; other; R0018624:Results | ||||
| A2 | events | 0 / 8 | not stated; other; R0018624:Results |
Death by suicide (2 lines; O35B)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 8 | not stated; other; R0018624:Results | ||||
| A2 | events | 0 / 8 | not stated; other; R0018624:Results |